The study analyzed the impact and cost-effectiveness of the TAK-003 dengue vaccine in Thailand. The dynamic model used took into account the spread of the virus between humans and mosquitoes, the four types of the virus and the seasonality of the disease. The TAK-003 vaccine can reduce the number of symptomatic dengue cases by 41-57% and hospitalizations by 47-70%. The greatest effect is expected with the routine vaccination of children at the age of 6 and supplementing the vaccination with another 10 age groups. The vaccine could prevent more than 100,000 lost health years (DALYs) and save up to $1.79 billion in society over 20 years. Vaccination at age 11, along with existing HPV vaccination, brings significant health and economic benefits. The vaccine is approved to protect against all four types of dengue virus. The study shows that TAK-003 vaccination can significantly reduce the burden of dengue and bring savings to the health care system.